The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Compounds of the formulae (I) or (II) ##STR00001##
wherein X is ##STR00002## A is O, S, NR.sub.5 or CR.sub.16R.sub.17; R.sub.1 is for example hydrogen or C.sub.1-C.sub.20alkyl R.sub.2 is for example hydrogen, C.sub.1-C.sub.20alkyl or C.sub.6-C.sub.20aryl R.sub.5 for example is C.sub.1-C.sub.20alkyl; R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 for example independently of each other are hydrogen. C.sub.1-C.sub.20alkyl, halogen, CN or NO.sub.2; Ar.sub.1 is for example unsubstituted or substituted C.sub.6-C.sub.20aryl, C.sub.3-C.sub.20heteroaryl, C.sub.6-C.sub.20aroyl, C.sub.3-C.sub.20heteroarylcarbonyl or ##STR00003## or Ar.sub.1 is ##STR00004## Ar.sub.2 is for example phenylene, ##STR00005##
all of which are unsubstituted or substituted M is for example unsubstituted or substituted C.sub.1-C.sub.20alkylene Y is a direct bond, O, S, NR.sub.5 or CO; Z.sub.1 is for example O or S; Z.sub.2 is a direct bond, O, S or NR.sub.5; and Q is CO or a direct bond.

Compounds of the formulae (I) or (II) ##STR00001##
wherein X is ##STR00002## A is O, S, NR.sub.5 or CR.sub.16R.sub.17; R.sub.1 is for example hydrogen or C.sub.1-C.sub.20alkyl R.sub.2 is for example hydrogen, C.sub.1-C.sub.20alkyl or C.sub.6-C.sub.20aryl R.sub.5 for example is C.sub.1-C.sub.20alkyl; R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 for example independently of each other are hydrogen. C.sub.1-C.sub.20alkyl, halogen, CN or NO.sub.2; Ar.sub.1 is for example unsubstituted or substituted C.sub.6-C.sub.20aryl, C.sub.3-C.sub.20heteroaryl, C.sub.6-C.sub.20aroyl, C.sub.3-C.sub.20heteroarylcarbonyl or ##STR00003## or Ar.sub.1 is ##STR00004## Ar.sub.2 is for example phenylene, ##STR00005##
all of which are unsubstituted or substituted M is for example unsubstituted or substituted C.sub.1-C.sub.20alkylene Y is a direct bond, O, S, NR.sub.5 or CO; Z.sub.1 is for example O or S; Z.sub.2 is a direct bond, O, S or NR.sub.5; and Q is CO or a direct bond.

Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer. ##STR00001##

Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer. ##STR00001##

The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.

The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.

The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.

The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.

The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.